Sangamo Therapeutics Stock Quote SGMO - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.92

Bid

0.914

Ask

0.92

Volume

56,528,203

0.7777 Day's Range 1.205

0.2911 52 Week Range 1.48

Market Cap

190.909M

Previous Close

0.8649

Open

1.01

Last Trade

0.914

Last Trade Time

Financial Volume

$ 52,088,054

VWAP

0.921453

Average Volume (3m)

9,686,813

Shares Outstanding

207,510,076

Dividend Yield

PE Ratio

-0.73

Earnings Per Share (EPS)

-1.24

Revenue

176.23M

Net Profit

-257.83M

Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemoph... Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.sangamo.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Sangamo Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker SGMO. The last closing price for Sangamo Therapeutics was $0.86. Over the last year, Sangamo Therapeutics shares have traded in a share price range of $ 0.2911 to $ 1.48.

Sangamo Therapeutics currently has 207,510,076 shares outstanding. The market capitalization of Sangamo Therapeutics is $179.48 million. Sangamo Therapeutics has a price to earnings ratio (PE ratio) of -0.73.

FeaturedCannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA

Form 8-K - Current report

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

Giroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.5312	136.625514403	0.3888	1.205	0.3726	86371929	0.65819382	CS
4	0.5228	131.621349446	0.3972	1.205	0.304	24378141	0.63978281	CS
12	0.3665	66.2149954833	0.5535	1.205	0.304	9686813	0.62472448	CS
26	0.49	113.953488372	0.43	1.48	0.304	5641061	0.66878751	CS
52	-0.41	-30.8270676692	1.33	1.48	0.2911	3682525	0.65138101	CS
156	-9.04	-90.7630522088	9.96	11.49	0.2911	2288901	2.36908757	CS
260	-11.32	-92.4836601307	12.24	19.43	0.2911	2052666	5.09684694	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
TWOU2U Inc	$ 2.70 (116.00%)	139.18M
LIPOLipella Pharmaceuticals Inc	$ 0.8576 (112.22%)	194.69M
NIPGNIP Group Inc	16.50 (82.93%)	7.04M
TIVCTivic Health Systems Inc	$ 0.7049 (55.95%)	106.15M
ISPOInspirato Inc	$ 5.15 (47.99%)	6.24M
CGTXCognition Therapeutics Inc	$ 1.32 (-44.30%)	26.32M
GRIGRI Bio Inc	$ 0.8334 (-33.86%)	1.14M
CEROCERo Therapeutics Holdings Inc	$ 0.1817 (-29.02%)	8.28M
PRSTPresto Technologies Inc	$ 0.0499 (-26.51%)	29.32M
TGLTreasure Global Inc	$ 1.40 (-24.32%)	80.79k
NVDANVIDIA Corporation	$ 111.59 (-1.30%)	248.03M
LIPOLipella Pharmaceuticals Inc	$ 0.8576 (112.22%)	194.69M
SQQQProShares UltraPro Short QQQ	$ 9.05 (-0.55%)	152.03M
TWOU2U Inc	$ 2.70 (116.00%)	139.18M
TSLATesla Inc	$ 232.10 (5.60%)	129.2M